Page 2 - Lupus Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

WireImage Lupus is unpredictable, triggering different symptoms in different patients. A chronic illness, it can even attack many different parts of the body. The condition is an autoimmune disease, which means that a person’s immune system—the body system that usually fights infections—attacks healthy tissue instead. It can cause inflammation and pain anywhere in a patient’s body. Because the illness can look different in every patient, it can go undetected and undiagnosed for years. The Lupus Foundation of America estimates that 1.5 million Americans and at least 5 million people w...

World Lupus Federation Global Survey of People with Lupus Finds Half of Respondents Experienced a Decrease in Access to Healthcare During COVID-19 Pandemic earlier than the general population WASHINGTON, April 21, 2021 /PRNewswire/ -- In a new global survey, more than 6,100 people with lupus from over 85 countries shared their recent experiences of the COVID-19 pandemic and their views of the COVID-19 vaccines. Half (50%) of the survey participants reported decreased access to at least one aspect of lupus healthcare during the last three months, including decreased access to their lupus docto...

Lupus Foundation of America Congratulates Aurinia Pharmaceuticals on FDA Approval of Lupkynis™ (voclosporin) to Treat Lupus Nephritis First FDA-approved oral treatment for lupus nephritis represents a significant milestone for people living with lupus-related kidney disease, a leading cause of disability and mortality in lupus News provided by Share this article Share this article WASHINGTON, Jan. 22, 2021 /PRNewswire/ --  For the second time in less than two months, the U.S. Food and Drug Administration (FDA) has approved a new medication to treat adults with lupus nephritis (lupus-relat...

Lupus Foundation of America Sees Big Win with FDA Approval of Benlysta for Lupus Nephritis News provided by Share this article Share this article WASHINGTON, Dec. 17, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Benlysta to treat lupus nephritis (lupus-related kidney disease) in adults. The approval is for both the intravenous and subcutaneous formulations. The decision makes Benlysta the first lupus therapy authorized to treat this potentially life-threatening complication of the disease. Up to 60 percent of people with lupus will develop lupus nephritis. Ben...